DE69435049D1 - Chimäre proteine zur vermeidung der komplementaktivierung - Google Patents

Chimäre proteine zur vermeidung der komplementaktivierung

Info

Publication number
DE69435049D1
DE69435049D1 DE69435049T DE69435049T DE69435049D1 DE 69435049 D1 DE69435049 D1 DE 69435049D1 DE 69435049 T DE69435049 T DE 69435049T DE 69435049 T DE69435049 T DE 69435049T DE 69435049 D1 DE69435049 D1 DE 69435049D1
Authority
DE
Germany
Prior art keywords
chimeric proteins
activation
complemental
avoiding
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69435049T
Other languages
German (de)
English (en)
Inventor
Jone-Long Ko
Paul J Higgins
C Grace Yeh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Application granted granted Critical
Publication of DE69435049D1 publication Critical patent/DE69435049D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69435049T 1993-09-24 1994-09-23 Chimäre proteine zur vermeidung der komplementaktivierung Expired - Lifetime DE69435049D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12659693A 1993-09-24 1993-09-24
US08/310,416 US5679546A (en) 1993-09-24 1994-09-22 Chimeric proteins which block complement activation
PCT/US1994/010786 WO1995008570A1 (en) 1993-09-24 1994-09-23 Chimeric proteins which block complement activation

Publications (1)

Publication Number Publication Date
DE69435049D1 true DE69435049D1 (de) 2008-01-24

Family

ID=26824842

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69435049T Expired - Lifetime DE69435049D1 (de) 1993-09-24 1994-09-23 Chimäre proteine zur vermeidung der komplementaktivierung

Country Status (9)

Country Link
US (2) US5679546A (enExample)
EP (1) EP0723555B1 (enExample)
JP (2) JP3860605B2 (enExample)
CN (1) CN1057097C (enExample)
AT (1) ATE380875T1 (enExample)
AU (1) AU697167B2 (enExample)
CA (1) CA2172610A1 (enExample)
DE (1) DE69435049D1 (enExample)
WO (1) WO1995008570A1 (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6482404B1 (en) 1989-10-12 2002-11-19 David James White Transplantation of tissue comprising a DNA sequence encoding a homologous complement restriction factor
US5866402A (en) * 1995-05-05 1999-02-02 Chiron Corporation Chimeric MCP and DAF proteins with cell surface localizing domain
FR2736916B1 (fr) * 1995-07-21 1997-09-19 Univ Paris Curie Proteines hetero-multimeriques recombinantes du type alpha-beta c4bp
CA2298475A1 (en) * 1997-10-31 1999-05-14 Walter Reed Army Institute Of Research Method of inhibiting side effects of pharmaceutical compositions containing amphiphilic vehicles or drug carrier molecules
ES2488819T3 (es) * 1998-02-20 2014-08-29 Genentech, Inc. Inhibidores de la activación del complemento
US7112327B2 (en) 1998-02-20 2006-09-26 Tanox, Inc. Inhibition of complement activation
US6956107B2 (en) * 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation
US6297024B1 (en) 1998-10-15 2001-10-02 Cell Activation, Inc. Methods for assessing complement activation
US6235494B1 (en) 1999-02-08 2001-05-22 The Scripps Research Institute Substrates for assessing mannan-binding protein-associated serine protease activity and methods using the substrates
WO2001032901A1 (en) * 1999-11-01 2001-05-10 Chiron Corporation Expression vectors, transfection systems, and method of use thereof
EP2896631A1 (en) 2000-10-10 2015-07-22 Genentech, Inc. Inhibition of complement C5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection
US6820011B2 (en) 2001-04-11 2004-11-16 The Regents Of The University Of Colorado Three-dimensional structure of complement receptor type 2 and uses thereof
NZ529044A (en) * 2001-06-08 2008-03-28 Novartis Ag Treatment or prophylaxis of insulin-producing cell graft rejection
EP1539811A4 (en) * 2002-09-16 2006-05-24 Elusys Therapeutics Inc PREPARATION OF BISPEQIFIC MOLECULES WITH POLYETHYLENE GLYCOL LINKER
PT1569685E (pt) * 2002-11-15 2012-11-02 Univ Colorado Regents Recetor do complemento 2 direcionado a moduladores do complemento
WO2005069726A2 (en) * 2004-01-21 2005-08-04 Case Western Reserve University Hybrid and chimeric polypeptides that regulate activation of complement
PT1713503E (pt) * 2004-02-10 2013-11-14 Nat Jewish Health Inibição do factor b, a via alternativa do complemento e métodos relacionados
US8703693B2 (en) * 2004-03-31 2014-04-22 The Feinstein Institute For Medical Research Adrenomedullin and adrenomedullin binding protein for ischemia/reperfusion treatment
AU2005231395B2 (en) * 2004-03-31 2011-06-16 The Fernstein Institute For Medical Research Adrenomedullin and adrenomedullin binding protein for ischemia/reperfusion treatment
CA2610340C (en) * 2005-05-26 2016-02-16 Vernon Michael Holers Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
KR20180002911A (ko) * 2005-11-04 2018-01-08 제넨테크, 인크. 안질환 치료를 위한 보체 경로 억제제의 용도
EP2044111B1 (en) 2006-06-21 2014-08-13 MUSC Foundation For Research Development Targeting complement factor h for treatment of diseases
CL2007003161A1 (es) * 2006-11-02 2008-05-30 Genentech Inc Anticuerpos anti-factor d; acidos nucleicos que los codifican; vector y linea celular que los comprenden; metodo de produccion; composicion farmaceutica que comprende a los anticuerpos; y su uso para tratar trastornos mediados por el complemento como
JP5332064B2 (ja) * 2007-03-01 2013-11-06 ウェルスタット イムノセラピューティクス， エルエルシー 炎症により特徴付けられる疾患の治療
CA2680344A1 (en) 2007-03-14 2008-11-20 Woodruff Emlen Humaneered anti-factor b antibody
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
US20090324585A1 (en) * 2008-06-12 2009-12-31 The Trustees of the Leland Standford Junior University Complement inhibitory agents as therapeutics in posttraumatic and degenerative arthritis
WO2011003098A1 (en) 2009-07-02 2011-01-06 Musc Foundation For Research Development Methods of stimulating liver regeneration
US10239937B2 (en) 2009-11-05 2019-03-26 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
CN102234332B (zh) * 2010-04-26 2014-12-17 浙江海正药业股份有限公司 一种重组人血白蛋白及其融合蛋白的分离纯化工艺
CN103038252A (zh) 2010-05-14 2013-04-10 科罗拉多大学董事会,法人团体 改良的补体受体2(cr2)靶向群
WO2011163412A1 (en) 2010-06-22 2011-12-29 The Regents Of The University Of Colorado, A Body Corporate Antibodies to the c3d fragment of complement component 3
BR112013005116A2 (pt) 2010-09-03 2019-09-24 Stem Centrx Inc moduladores e métodos de uso
US10039802B2 (en) 2011-06-22 2018-08-07 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
AU2013243570B2 (en) 2012-04-03 2017-12-14 Novelmed Therapeutics, Inc. Humanized and chimeric anti-factor Bb antibodies and uses thereof
US9803005B2 (en) 2012-05-24 2017-10-31 Alexion Pharmaceuticals, Inc. Humaneered anti-factor B antibody
JP2015535212A (ja) 2012-08-17 2015-12-10 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト 補体活性化を検出するための組成物および方法
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
BR112016002845A2 (pt) 2013-08-12 2017-09-12 Genentech Inc composições e métodos para tratar condições associadas ao complemento
SG10202104175YA (en) 2014-02-27 2021-06-29 Allergan Inc COMPLEMENT FACTOR Bb ANTIBODIES
EP3137503A1 (en) 2014-05-01 2017-03-08 Genentech, Inc. Anti-factor d antibody variants and uses thereof
JP2018503368A (ja) 2014-12-18 2018-02-08 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｄｃを誘発する抗体を決定するためのアッセイ法および方法
IL296929B2 (en) * 2015-09-24 2025-07-01 Univ Pennsylvania Composition and method for treating complement-mediated disease
WO2017075252A1 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibody variant conjugates and uses thereof
JP2018534930A (ja) 2015-10-30 2018-11-29 ジェネンテック， インコーポレイテッド 抗ｄ因子抗体及びコンジュゲート
LT3394089T (lt) * 2015-12-23 2021-11-25 eleva GmbH Polipeptidai, skirti komplemento aktyvacijos inhibicijai
DK3474883T3 (da) 2016-06-28 2022-08-29 Univ Ulm Komplementinhibitorer og anvendelser deraf
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
EP3956347A4 (en) * 2019-04-13 2023-09-20 National Centre For Cell Science DAF-MCP CHIMERIC PROTEINS, THEIR MANUFACTURING METHOD AND USE OF THE CHIMERIC PROTEIN TO TREAT PATHOLOGICAL CONDITIONS INVOLVING THE COMPLEMENT SYSTEM

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5212071A (en) * 1988-04-01 1993-05-18 The Johns Hopkins University Nucleic acids encoding a human C3b/C4b receptor (CR1)
US4774180A (en) * 1986-02-26 1988-09-27 Massachusetts Institute Of Technology Construction and application of polyproteins
US5264357A (en) * 1985-05-24 1993-11-23 Genentech, Inc. Nucleic acids vectors and cells for the synthesis of membrane anchor fusion polypeptides
IL82390A0 (en) * 1986-05-02 1987-10-30 Genentech Inc Nucleic acid and methods for the synthesis of novel daf compositions
DK0489116T3 (da) * 1989-08-22 1994-05-02 Immunex Corp Fusionsproteiner omfattende GM-CSF og IL-3
CA2049964A1 (en) * 1990-01-26 1991-07-27 Mark P. Pasek C4 binding protein fusion proteins
EP1413587A2 (en) * 1991-05-03 2004-04-28 Washington University Modified complement system regulator
US5252216A (en) * 1992-03-24 1993-10-12 Smithkline Beecham Corporation Protein purification
US5627264A (en) * 1994-03-03 1997-05-06 Alexion Pharmaceuticals, Inc. Chimeric complement inhibitor proteins

Also Published As

Publication number Publication date
JPH09502985A (ja) 1997-03-25
JP3860605B2 (ja) 2006-12-20
CN1138863A (zh) 1996-12-25
WO1995008570A1 (en) 1995-03-30
US5679546A (en) 1997-10-21
AU8071994A (en) 1995-04-10
EP0723555A1 (en) 1996-07-31
EP0723555B1 (en) 2007-12-12
AU697167B2 (en) 1998-10-01
EP0723555A4 (en) 1999-04-28
ATE380875T1 (de) 2007-12-15
CA2172610A1 (en) 1995-03-30
JP2005041882A (ja) 2005-02-17
US5851528A (en) 1998-12-22
CN1057097C (zh) 2000-10-04

Similar Documents

Publication Publication Date Title
DE69435049D1 (de) Chimäre proteine zur vermeidung der komplementaktivierung
ATE226634T1 (de) Fibronektin bindendes protein
NO971875D0 (no) Cathepsin 02 protease
DK105489D0 (da) Polypeptid
DK1175909T3 (da) Terapeutiske sammensætninger af antistoffer og antisense-nukleinsyrer mod Serrate
ATE319818T1 (de) Polypeptide mit aminopeptidaseaktivität und für diese kodierende nukleinsäuren
BR9911549A (pt) Processo de produção de fitase em levedura
ATE389023T1 (de) Kontrolle der schotendehiszenz
EP0422125A4 (en) Platelet blocking peptides
DE69837475D1 (de) Polypeptide mit aminopeptidaseaktivität und dafür kodierende nukleinsäuren
DE69737651D1 (de) Cortistatin: neuropeptide, zusammensetzungen und methoden
ES2058479T3 (es) Compuestos peptidicos.
DE69634077D1 (de) Haemophilus adhäsionsproteinen
FI930626A0 (fi) Proteinstruktur hos vaexttoxingelonin
PT635025E (pt) Processo para preparar proteinas modificadas
AU669149B2 (en) Expression signal-peptide-free staphylokinases
ATE550345T1 (de) Sfrp, mit sfrp-interagierende peptidmotive sowie verwendungsverfahren
ES2052513T3 (es) Nuevos polipeptidos, su fabricacion y empleo.
DE3881123D1 (de) Klonieren von fuer einen antibakteriellen polypeptidvorlaeufer kodierender dna und expression des vorlaeufers.
AU637589B2 (en) Ancrod proteins, their production and use
DE69033553D1 (de) Rekombinante herstellung von laktoperoxidase
ATE231887T1 (de) Protein mit anti-tumorwirkung
SE9604439D0 (sv) New receptor
ATE76081T1 (de) Verfahren zur herstellung von dipeptiden mit nterminalen nichtproteinogenen aminosaeuren.
ATE93893T1 (de) Expressionssysteme zur ueberproduktion gewuenschter proteine.

Legal Events

Date Code Title Description
8332 No legal effect for de